GET DAILY SIGNALSOneMedNet Corporation (ONMD): Can It Reach the $7.50 Technical Milestone?
Key Takeaways
- The $7.50 central target is a technical objective derived from public discussion, not an analyst consensus — no verifiable analyst price targets currently cover the stock.
- The target represents a recovery back toward and above the 200-day moving average near $7.09, a commonly watched milestone for micro-cap names.
- At the latest close near $5.14, reaching $7.50 requires roughly a 46% gain — a substantial move for a company of this size.
- There is no usable analyst target range; the only notable rating is a non-price-target "Sell" from Weiss Ratings, while other published figures appear to be data errors.
- The strongest supports are sharply rising contract bookings, a large healthcare data network, and structural demand for AI-ready medical data.
- The biggest risks are a going-concern warning, negative gross margins, minimal cash, and a recent 1-for-10 reverse stock split.
- Explore more context on the ticker's Major News, Today's Price Move, Forecast, and Earnings pages.
- Discover Trending AI Robots for AI-driven market scanning and signal ideas.
Setting the $7.50 Target
OneMedNet Corporation (ONMD) lacks a usable analyst consensus. MarketBeat lists no consensus price target, and the sole rating is a "Sell" from Weiss Ratings with no numeric objective; figures circulating on some aggregator sites (such as a $293 average) are clearly erroneous or data-entry artifacts. Because no credible analyst target exists, this article applies a fallback approach: the $7.50 figure reflects a technical milestone that is actively relevant to the stock — a return toward the 200-day moving average near $7.09 and the round-number $7.50 level just above it. It is a publicly discussed technical objective, not a Wall Street price forecast. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where ONMD Stands Today and the Road Ahead
ONMD closed near $5.14, within a split-adjusted 52-week range of $3.61 to $23.00, giving the company a market capitalization of roughly $30 million. Reaching $7.50 from that level implies about 46% upside, which is a substantial move. The path would most likely require evidence that the company's reported bookings are converting into recognized revenue and that gross margins are turning positive. The shares currently trade below both the 50-day moving average near $5.41 and the 200-day moving average near $7.09, meaning the first step toward $7.50 would be reclaiming those averages on higher volume.
Factors That Could Drive the Stock Higher
The bull case centers on demand. OneMedNet reported record 2025 contract bookings of $2.79 million, more than four times the prior year, and has since pointed to a sharp further increase in 2026 bookings, including a July agreement valued at more than $11.5 million to supply imaging data for a foundational AI model. The company describes a network spanning more than 2,300 healthcare sites, over 90 million patient journeys and 270 million clinical studies. If large licensing deals begin to convert into recurring, higher-margin subscription revenue, the current roughly 15–20x price-to-sales (P/S) multiple could look more justified, and sentiment in the AI-healthcare data space could lift the shares back toward the $7 area.
Key Risks and Challenges Ahead
The obstacles are structural. In the quarter ended June 30, 2026, OneMedNet reported only about $292,000 of revenue against a net loss of roughly $2.2 million, with negative gross margins — the cost of delivering data currently exceeds what customers pay. Trailing-twelve-month revenue is near $1.46 million, while the net loss runs about $8.4 million. Cash and investments totaled roughly $358,000 at quarter-end, against about $6.9 million in trailing operating cash outflow, which points to further dilutive capital raising. The company has flagged going-concern risk in its SEC filings and completed a 1-for-10 reverse stock split in late September 2026 to regain Nasdaq's minimum bid price requirement. These factors argue that the gap between announced bookings and recognized revenue, not the headline contract values, will decide the stock's direction.
Important Technical Levels to Watch
The most relevant levels are the 50-day moving average near $5.41, the 200-day moving average near $7.09, and the round $7.50 objective. The shares trade below both averages after a prolonged decline from a 52-week high of $23.00, with a 52-week low near $3.61. A sustained move above the 50-day average would be an early sign of stabilization, while reclaiming the 200-day average would put the $7.50 milestone within reach. The low share float of roughly two million shares also means trading can be volatile in either direction. From what I see, the technical structure remains the primary lens here until fundamentals catch up.
What to Monitor Going Forward
Unlike conventional analyst targets, which typically reflect a roughly 12-month horizon, the $7.50 technical objective carries no formal timeframe. Investors should watch the next quarterly results (Q3 figures were expected around late November 2026), specifically recognized revenue versus reported bookings, gross margin trajectory, cash burn, and any new financing or channel-partner agreements. Additional capital raises, listing-compliance updates and any shift in AI-related investor sentiment toward micro-cap data providers are also relevant. These developments are more meaningful to the target than any single technical reading. I’m watching this closely as execution on the bookings pipeline will be decisive.
Final Assessment
The question of whether ONMD can reach $7.50 is, at its core, a question about whether the company can begin converting an impressive bookings pipeline into profitable revenue. The roughly 46% move required is substantial, and the absence of credible analyst coverage means the target is a technical and valuation objective rather than a published forecast. The strongest support is real demand for regulatory-grade, AI-ready medical imaging data, but the going-concern warning, negative gross margins, thin cash position and dilutive financing history are equally real obstacles. Investors should focus on revenue conversion and margin improvement in upcoming quarterly reports, and treat any movement toward $7.50 as dependent on execution rather than on the size of announced contracts.
Using Tickeron’s AI Daily Buy/Sell Signals for Ongoing Monitoring
In my own research process, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to track names like this one. The tool applies artificial intelligence to scan market conditions and technical patterns across thousands of stocks, delivering daily signals that help flag potential shifts in momentum. For a micro-cap with limited analyst coverage, it serves as a useful complement to reviewing bookings trends and financial filings, allowing quicker identification of stabilization or renewed weakness.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ONMD in -5.38% downward trend, falling for three consecutive days on October 30, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ONMD declined for three days, in 218 of 241 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
ONMD broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ONMD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ONMD's RSI Indicator exited the oversold zone, 18 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 35 of 57 cases where ONMD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 61%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ONMD as a result. In 41 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.
The Moving Average Convergence Divergence (MACD) for ONMD just turned positive on October 21, 2026. Looking at past instances where ONMD's MACD turned positive, the stock continued to rise in 30 of 57 cases over the following month. The odds of a continued upward trend are 53%.
ONMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +43.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONMD advanced for three days, in 113 of 149 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. ONMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ONMD's P/B Ratio (-86.621) is very low in comparison to the industry average of (4.477). P/E Ratio (-3.024) is within average values for comparable stocks, (13.414). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. ONMD's P/S Ratio (23.529) is slightly higher than the industry average of (6.065).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement